When shares of Optimer (NASDAQ: OPTR) jumped up in February on the news that it was seeking "strategic alternatives" -- in other words, looking for a buyer -- Motley Fool health-care analyst David Williamson warned that the company's defining drug, Dificid, has had slow sales, and finding a buyer might not be easy. However, in this video, David tells investors about an article in Bloomberg, reporting that both GlaxoSmithKline (GSK 2.20%) and AstraZeneca (AZN 2.59%) may be interested, which has shares of Optimer up 20%. David explores what Optimer has to offer that may or may not make this buyout worth the buyer's while.
Is This Really Big Pharma's Next Acquisition?
By Dave Williamson
-
Apr 2, 2013 at 5:14PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Where did all this buyout interest come from?
Stocks Mentioned

Merck & Co., Inc.
MRK
$93.55
(1.58%)
$1.46

GlaxoSmithKline plc
GSK
$44.52
(2.20%)
$0.96

AstraZeneca PLC
AZN
$66.21
(2.59%)
$1.67

Cubist Pharmaceuticals LLC
CBST.DL
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles

Better Buy: Gingko Bioworks vs. Amyris

Have $2,000? 2 Market Crash-Ready Stocks to Buy

Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever

2 Safe Stocks to Buy in a Bear Market

Tech Stock Sell-Off Got You Scared? Here's a Better Buy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.